biomarkers
- Access DeniedDecline in Left Ventricular Ejection Fraction Following Anthracyclines Predicts Trastuzumab CardiotoxicityShom Goel, Jane Beith, et al.JACC: Heart Failure
- Access DeniedSex-Specific Epidemiology of Heart Failure Risk and Mortality in EuropeResults From the BiomarCaRE ConsortiumChristina Magnussen, on behalf of the BiomarCaRE Consortium, et al.JACC: Heart Failure
- Access DeniedIntegrative Assessment of Congestion in Heart Failure Throughout the Patient JourneyNicolas Girerd, on behalf of INI-CRCT, Great Network, and the EF-HF Group, et al.JACC: Heart Failure
- Access DeniedHigh-Sensitivity Cardiac Troponin and New-Onset Heart FailureA Systematic Review and Meta-Analysis of 67,063 Patients With 4,165 Incident Heart Failure EventsJonathan D.W. Evans, Peter Willeit, et al.JACC: Heart Failure
- Access DeniedBiomarker Profiles of Acute Heart Failure Patients With a Mid-Range Ejection FractionJasper Tromp, Peter van der Meer, et al.JACC: Heart Failure
- Access DeniedTheory and FactRevisiting Association and CausationStephen S. GottliebJACC: Heart Failure
- Access DeniedInteraction Between Spironolactone and Natriuretic Peptides in Patients With Heart Failure and Preserved Ejection FractionFrom the TOPCAT TrialInder S. Anand, Scott D. Solomon, et al.JACC: Heart Failure
- Access DeniedLimited Added Value of Circulating Inflammatory Biomarkers in Chronic Heart FailureStåle H. Nymo, on behalf of the CORONA Study Group, et al.JACC: Heart Failure
- Access DeniedCan Carbohydrate Antigen-125 Be a New Biomarker to Guide Heart Failure Treatment?The CHANCE-HF TrialAntonio D’Aloia, Marco Metra, et al.JACC: Heart Failure
- Access DeniedGalectin-3 After Heart TransplantationDoes it Get Better?Alan Maisel, William Stendardi, et al.JACC: Heart Failure
Pages
Advertisement